Current targets and treatments of schizophrenia

Abstract

With the improvement of the level of social and economic development, mental illness has received more and more attention and attention. Among them, schizophrenia, as a common mental illness, seriously impairs the mental activity and social function of patients, and its lifetime prevalence rate is about 1%, bringing a heavy social burden. Schizophrenia is a disease that involves a variety of symptoms, including cognitive, behavioral, and emotional, and its symptoms vary greatly from patient to patient, even at different stages of the disease in the same patient. At present, the specific pathogenesis of schizophrenia is still unclear, and it is generally believed that it is caused by structural and functional abnormalities of the central nervous system, which is the result of the interaction of genetic and environmental factors. Schizophrenia is a mental disorder disease, It can cause a person to be out of control in a number of ways and is a common and popular mental illness in the world, and recently, with advances and pioneering in the field of medicine, more and more neuroscientists and medical doctors are beginning to development into this field. This review systematically introduces several pathways related to schizophrenia disorders, anti-psychotic medications, and the GABA and schizophrenia. This review also introduces three generations Antipsychotics and further discusses role of GABA in the pathogenesis of schizophrenia.